Irritable bowel syndrome and chronic constipation: Emerging drugs, devices, and surgical treatments

被引：44

作者：

Harris L.A. ^{[1
]}

Hansel S. ^{[1
]}

DiBaise J. ^{[1
]}

Crowell M.D. ^{[1
]}

机构：

[1] Division of Gastroenterology, Mayo Clinic, Scottsdale, AZ 85259

来源：

Current Gastroenterology Reports | 2006年 / 8卷 / 4期

关键词：

Irritable Bowel Syndrome; Irritable Bowel Syndrome Patient; Chronic Constipation; Rifaximin; Tegaserod;

D O I：

10.1007/s11894-006-0048-y

中图分类号：

学科分类号：

摘要：

Irritable bowel syndrome (IBS) and chronic constipation (CC) are two of the most common functional disorders of the gut. CC and IBS are estimated to affect up to 20% and 27% of the North American population respectively. Although not life-threatening, CC and IBS can profoundly and negatively affect quality of life and are associated with a significant economic burden related to direct and indirect annual health-care costs. Possible etiologies for IBS and CC include alterations in visceral sensation and gastrointestinal motility. IBS may be caused by disturbances in brain-gut interactions affecting gastrointestinal motility and visceral sensitivity. Research efforts in CC have begun to identify abnormalities in myenteric neurons, alterations in neurotransmitters and their receptors, and incoordination of the muscles of the pelvic floor or anorectum. Both disorders may be influenced by genetic predisposition, environmental factors, and stress. In this article, the safety and efficacy of traditional and emerging therapies for CC and IBS are examined. In addition, their pathophysiology and symptoms are briefly reviewed. Copyright © 2006 by Current Science Inc.

引用

页码：282 / 290

页数：8

共 73 条

[1]

Evidence-based position statement on the management of irritable bowel syndrome in North America, Am J Gastroenterol., 97, 11 SUPPL., (2002)

[2]

Harris L., Chang L., The functional bowel spectrum, Textbook of Fibromyalgia and Other Non-Neuropathic Pain Syndromes, (2005)

[3]

Tillisch K., Labus J., Naliboff B., Et al., Characterization of the alternating bowel habit subtype in patients with irritable bowel syndrome, Am J Gastroenterol, 100, pp. 896-904, (2005)

[4]

Tillisch K., Chang L., Diagnosis and treatment of irritable bowel syndrome: State of the art, Current Gastroenterol Rep, 7, pp. 249-256, (2005)

[5]

Drossman D.A., Whitehead W.E., Camilleri M., Irritable bowel syndrome: A technical review for practice guideline development, Gastroenterology, 112, pp. 2120-2137, (1997)

[6]

Martin R., Barron J.J., Zacker C., Irritable bowel syndrome: Toward a cost-effective management approach, Am J Manag Care, 7, (2001)

[7]

Drossman D.A., Camilleri M., Mayer E.A., Whitehead W.E., AGA technical review on irritable bowel syndrome, Gastroenterology, 123, pp. 2108-2131, (2002)

[8]

Cole J.A., Yeaw J.M., Cutone J.A., Et al., The incidence of abdominal and pelvic surgery among patients with irritable bowel syndrome, Dig Dis Sci, 50, pp. 2268-2275, (2005)

[9]

Chang L., Heitkemper M.M., Gender differences in irritable bowel syndrome, Gastroenterology, 123, pp. 1686-1701, (2002)

[10]

Mertz H., Naliboff B., Munakata J., Et al., Altered rectal perception is a biological marker of patients with irritable bowel syndrome, Gastroenterology, 109, pp. 40-52, (1995)

← 1 2 3 4 5 6 7 8 →